JAKARTA, Sept. 30 (Xinhua) -- The Indonesian food and drug administration (BPOM) has issued an emergency use authorization (EUA) for the mRNA-platform COVID-19 vaccine, AWcorna, developed by Chinese companies.
AWcorna is a SARS-CoV-2 mRNA vaccine developed by Suzhou Abogen Biosciences Co., Ltd. with the participation of Walvax Biotechnology Co., Ltd. AWcorna can be stored and transported at two to eight degrees centigrade.
"The AWcorna vaccine has been approved for EUA to prevent infection with the SARS CoV-2 virus in individuals aged 18 years and above, as a primary and heterologous booster dose," said Penny Lukito, head of BPOM, at a press conference on Friday in Jakarta.
The EUA for the primary 2-dose series is based on safety and efficacy data from the pivotal phase 3 clinical trials, currently ongoing in 31 sites of 3 countries including Indonesia.
